Marks designated
®
and
™
are owned by Shire or an affi liated company.
©2016 Shire US Inc. Lexington, MA 02421 S12041 07/16
Indication
Xiidra
™
(lifi tegrast ophthalmic solution) 5% is indicated
for the treatment of signs and symptoms of dry eye
disease (DED).
Important Safety Information
In clinical trials, the most common adverse reactions
reported in 5-25% of patients were instillation site
irritation, dysgeusia and reduced visual acuity.
Other adverse reactions reported in 1% to 5% of the
patients were blurred vision, conjunctival hyperemia,
eye irritation, headache, increased lacrimation, eye
discharge, eye discomfort, eye pruritus and sinusitis.
To avoid the potential for eye injury or contamination
of the solution, patients should not touch the tip of
the single-use container to their eye or to any surface.
Contact lenses should be removed prior to the
administration of Xiidra and may be reinserted
15 minutes following administration.
Safety and effi cacy in pediatric patients below
the age of 17 years have not been established.
For additional safety information, see accompanying
Brief Summary of Safety Information on the following
page and Full Prescribing Information on Xiidra-ECP.com.
The fi rst prescription eye drop FDA-approved to treat
both the signs and symptoms of Dry Eye Disease
THIINGS
